<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> is a cause of cardiac dysfunction, reduced myocardial perfusion, and ultimately <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Nerve growth factor (NGF) exerts protective effects on the cardiovascular system </plain></SENT>
<SENT sid="2" pm="."><plain>This study investigated whether NGF gene transfer can prevent diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> in mice </plain></SENT>
<SENT sid="3" pm="."><plain>We worked with mice with <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-induced type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and with nondiabetic control mice </plain></SENT>
<SENT sid="4" pm="."><plain>After having established that <z:mp ids='MP_0002055'>diabetes</z:mp> reduces cardiac NGF <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression, we tested NGF gene therapies with adeno-associated <z:mp ids='MP_0001799'>viral</z:mp> vectors (AAVs) for the capacity to protect the diabetic mouse heart </plain></SENT>
<SENT sid="5" pm="."><plain>To this aim, after 2 weeks of <z:mp ids='MP_0002055'>diabetes</z:mp>, cardiac expression of human NGF or β-<z:chebi fb="125" ids="28260">Gal</z:chebi> (control) genes was induced by either intramyocardial injection of AAV serotype 2 (AAV2) or systemic delivery of AAV serotype 9 (AAV9) </plain></SENT>
<SENT sid="6" pm="."><plain>Nondiabetic mice were given AAV2-β-<z:chebi fb="125" ids="28260">Gal</z:chebi> or AAV9-β-<z:chebi fb="125" ids="28260">Gal</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>We found that the diabetic mice receiving NGF gene transfer via either AAV2 or AAV9 were spared the progressive deterioration of cardiac function and left ventricular chamber <z:mpath ids='MPATH_66'>dilatation</z:mpath> observed in β-<z:chebi fb="125" ids="28260">Gal</z:chebi>-injected diabetic mice </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, they were additionally protected from myocardial microvascular rarefaction, hypoperfusion, increased deposition of interstitial <z:mp ids='MP_0003045'>fibrosis</z:mp>, and <z:mp ids='MP_0006042'>increased apoptosis</z:mp> of endothelial cells and cardiomyocytes, which afflicted the β-<z:chebi fb="125" ids="28260">Gal</z:chebi>-injected diabetic control mice </plain></SENT>
<SENT sid="9" pm="."><plain>Our data suggest therapeutic potential of NGF for the prevention of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> in diabetic subjects </plain></SENT>
</text></document>